dazoxiben

RN given refers to parent cpd

Also Known As:

4-(2-(1H-imidazol-1-yl)ethoxy)benzoic acid hydrochloride; UK 37248; UK 37248-01; UK-37,248; UK-37,248-01; UK-37248; dazoxiben hydrochloride; Benzoic acid, 4-(2-(1H-imidazol-1-yl)ethoxy)-

Networked: 58 relevant articles (6 outcomes, 4 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Imidazoles: 150
      - dazoxiben: 58

Experts

1.	Guo, X: 1 article (03/2021)
2.	Li, J: 1 article (03/2021)
3.	Li, L: 1 article (03/2021)
4.	Liu, N: 1 article (03/2021)
5.	Liu, R: 1 article (03/2021)
6.	Liu, X: 1 article (03/2021)
7.	Ma, W: 1 article (03/2021)
8.	Yang, Y: 1 article (03/2021)
9.	Zhou, X: 1 article (03/2021)
10.	Zhu, X: 1 article (03/2021)

Related Diseases

1.	Sudden Death 12/01/1985 - "In contrast, the thromboxane synthetase inhibitor, dazoxiben, was effective in inhibiting AA induced sudden death, but was without any effect when 9,11-methanoepoxy-PGH2 was used as the challenging agent. " 07/15/1986 - "The purpose of this study was to compare the effects of dazoxiben (DAZ), UK 38,485 (UK) and aspirin (ASA) in the prevention of thrombotic sudden death in rabbits. " 07/15/1986 - "Dazoxiben, UK 38,485 and aspirin: duration of effect for preventing thrombotic sudden death in rabbits."
2.	Pulmonary Hypertension 08/01/1986 - "Dazoxiben blocked the increase in plasma TXB2, prevented pulmonary hypertension, and attenuated the increase in EVLW after E. " 06/01/1985 - "Therefore, administration of dazoxiben in patients with ARDS does not decrease pulmonary hypertension. " 04/01/1985 - "The thromboxane synthetase inhibitor dazoxiben has improved survival and decreased pulmonary hypertension in experimental endotoxemia. " 04/01/1990 - "The thromboxane synthetase inhibitor dazoxiben, and the thromboxane receptor antagonist, SQ 29,548, similarly inhibited LPS-primed pulmonary hypertension and edema after PAF-stimulation. "
3.	Ventricular Fibrillation 01/01/1983 - "3 UK 37248 did not significantly alter the number of arrhythmias or the incidence of ventricular fibrillation resulting from coronary artery occlusion. " 01/01/1983 - "Effects of dazoxiben on arrhythmias and ventricular fibrillation induced by coronary artery occlusion and reperfusion in anaesthetised greyhounds." 01/01/1983 - "5 This latter result suggests that thromboxane may be an important factor in reperfusion induced ventricular fibrillation and that dazoxiben may be a useful drug in clinically related situations." 01/01/1985 - "The evidence is that in anaesthetised greyhound dogs, blockade of the thromboxane receptor (AH 23848) or inhibition of thromboxane synthesis (with a variety of "specific" inhibitors of thromboxane synthetase such as dazoxiben, dazmegrel, and "low-dose" aspirin) slightly reduces the severity of ischaemia-induced arrhythmias and markedly increases survival after myocardial reperfusion by reducing reperfusion-induced ventricular fibrillation (e.g., from 80% in control dogs to less than 20% in treated dogs). "
4.	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 04/01/1985 - "Dazoxiben in human sepsis and adult respiratory distress syndrome." 06/01/1985 - "Administration of dazoxiben, a selective thromboxane synthetase inhibitor, in the adult respiratory distress syndrome." 04/01/1985 - "A randomized prospective study of 10 patients with the clinical diagnosis of sepsis and early adult respiratory distress syndrome (hypoxemia, radiologic evidence of the syndrome, and intrapulmonary shunt greater than 20%) was performed to test the efficacy of dazoxiben in ameliorating the effects of human sepsis. "
5.	Edema (Dropsy) 03/15/1989 - "Inhibition of TxA2 synthetase using Dazoxiben prevented the pulmonary vasoconstriction and edema response to IL-2. In addition, IL-2 had no effect on the transendothelial clearance of 125I-albumin. " 04/01/1990 - "The thromboxane synthetase inhibitor dazoxiben, and the thromboxane receptor antagonist, SQ 29,548, similarly inhibited LPS-primed pulmonary hypertension and edema after PAF-stimulation. "

Related Drugs and Biologics

1.	Thromboxane-A Synthase
2.	Thromboxanes
3.	Aspirin (Acetylsalicylic Acid)
4.	dazmegrel
5.	Thromboxane Receptors (Thromboxane Receptor)
6.	Ligases (Synthetase)
7.	Endotoxins
8.	Albumins
9.	AH 23848
10.	dazoxiben

Related Therapies and Procedures

1.	Aftercare (After-Treatment)
2.	Prostheses and Implants (Prosthesis)
3.	Lasers (Laser)
4.	Oral Administration